[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]

Ken Takase, Toshihiro Miyamoto

Research output: Contribution to journalArticle

Abstract

In the past two decades, autologous hematopoietic stem cell transplantation (HSCT) in combination with novel agents such as bortezomib, thalidomide, and lenalidomide have dramatically prolonged the survival of patients with multiple myeloma (MM), however, MM still remains incurable. Allogeneic HSCT can be a potentially curative therapy for MM through the graft-versus-myeloma (GVM) effect, but allogeneic HSCT is not regarded as a standard therapy because of high incidence of treatment-related mortality. Several studies have been employed to investigate efficacy of reduced-intensity conditioning regimens, autologous HSCT followed by consecutive allogeneic HSCT, and introduction of novel agents prior to and/or after allogeneic HSCT.

Original languageEnglish
Pages (from-to)107-113
Number of pages7
JournalNihon rinsho. Japanese journal of clinical medicine
Volume73
Issue number1
Publication statusPublished - Jan 1 2015

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of '[Allogeneic hematopoietic stem cell transplantation for multiple myeloma]'. Together they form a unique fingerprint.

  • Cite this